- Home
- CHGG vs DMAC Comparison
CHGG vs DMAC Comparison
Compare CHGG & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHGG
- DMAC
- Stock Information
- Founded
- CHGG 2005
- DMAC 2000
- Country
- CHGG United States
- DMAC United States
- Employees
- CHGG N/A
- DMAC N/A
- Industry
- CHGG Other Consumer Services
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- CHGG Real Estate
- DMAC Health Care
- Exchange
- CHGG Nasdaq
- DMAC Nasdaq
- Market Cap
- CHGG 179.9M
- DMAC 185.1M
- IPO Year
- CHGG 2013
- DMAC N/A
- Fundamental
- Price
- CHGG $1.72
- DMAC $4.01
- Analyst Decision
- CHGG Hold
- DMAC Strong Buy
- Analyst Count
- CHGG 10
- DMAC 3
- Target Price
- CHGG $4.75
- DMAC $7.00
- AVG Volume (30 Days)
- CHGG 4.2M
- DMAC 41.6K
- Earning Date
- CHGG 11-12-2024
- DMAC 11-13-2024
- Dividend Yield
- CHGG N/A
- DMAC N/A
- EPS Growth
- CHGG N/A
- DMAC N/A
- EPS
- CHGG N/A
- DMAC N/A
- Revenue
- CHGG $662,077,000.00
- DMAC N/A
- Revenue This Year
- CHGG N/A
- DMAC N/A
- Revenue Next Year
- CHGG N/A
- DMAC N/A
- P/E Ratio
- CHGG N/A
- DMAC N/A
- Revenue Growth
- CHGG N/A
- DMAC N/A
- 52 Week Low
- CHGG $1.34
- DMAC $2.14
- 52 Week High
- CHGG $11.48
- DMAC $4.95
- Technical
- Relative Strength Index (RSI)
- CHGG 50.51
- DMAC 38.92
- Support Level
- CHGG $1.34
- DMAC $4.19
- Resistance Level
- CHGG $1.91
- DMAC $4.39
- Average True Range (ATR)
- CHGG 0.14
- DMAC 0.18
- MACD
- CHGG 0.01
- DMAC -0.04
- Stochastic Oscillator
- CHGG 64.66
- DMAC 6.00
About CHGG Chegg Inc.
Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Subscription Services, which encompasses Chegg Study Pack, Chegg Study, Chegg Writing, Chegg Math, and Busuu offerings that can be accessed internationally through the company's websites and on mobile devices, and Skills and Other, which encompasses skills, advertising services, print textbooks, and eTextbooks offerings.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.